| 今开：5.12 | 昨收：5.075 |
| 最高：5.15 | 最低：4.98 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：7.47596018E8 |
Ocular Therapeutix(OCUL)02-14 06:25
$Ocular Therapeutix(OCUL)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-021601 Act: 34 Size: 13 KB 网页链接查看全文
Ocular Therapeutix(OCUL)02-01 03:15
$Ocular Therapeutix(OCUL)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001086364-24-006007 Act: 34 Size: 13 KB 网页链接查看全文
Ocular Therapeutix(OCUL)02-03 08:05
$Ocular Therapeutix(OCUL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-010231 Size: 7 KB 网页链接查看全文
Ocular Therapeutix(OCUL)02-03 08:05
$Ocular Therapeutix(OCUL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-010233 Size: 5 KB 网页链接查看全文
Ocular Therapeutix(OCUL)02-22 20:45
$Ocular Therapeutix(OCUL)$ 8-K Current report, items 1.01, 2.02, 3.02, 5.02, 8.01, and 9.01 Accession Number: 0001104659-24-026324 Act: 34 Size: 922 KB 网页链接查看全文
Ocular Therapeutix(OCUL)02-07 07:35
$Ocular Therapeutix(OCUL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-011195 Size: 10 KB 网页链接查看全文
Ocular Therapeutix(OCUL)02-07 07:45
$Ocular Therapeutix(OCUL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-24-011200 Size: 10 KB 网页链接查看全文
Ocular Therapeutix(OCUL)02-06 05:35
$Ocular Therapeutix(OCUL)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-000656 Act: 33 Size: 6 KB 网页链接查看全文
Ocular Therapeutix(OCUL)03-30 05:15
$Ocular Therapeutix(OCUL)$ 8-K Current report, item 8.01 Accession Number: 0001104659-24-041224 Act: 34 Size: 190 KB 网页链接查看全文
Ocular Therapeutix(OCUL)04-19 04:15
$Ocular Therapeutix(OCUL)$ 8-K Current report, items 5.02 and 9.01 Accession Number: 0001104659-24-048850 Act: 34 Size: 207 KB 网页链接查看全文
比尔吉沃特TIGIT2023-12-17 22:54
$Ocular Therapeutix(OCUL)$$美国生科ETF-SPDR(XBI)$
目前商业化的是炎症药物Dextenza，今年YoY估计有25%；
2024Q1，青光眼的 OTX-TIC phase2 data readout；
2024Q2，Non-proliferative diabetic retinopathy的phase1 data readout。
截止Q3，公司还有现金1.03亿美元，催化剂集...查看全文
牛唐2023-06-16 17:08
医药板块速评（2022.06.15）
1、美国债务上限问题解决，美债后续走势如何看？
2、$Ocular Therapeutix(OCUL)暴跌，是否有抄底机会？
3、$C3.ai(AI)$ 、$Sonnet(SONN) 、$The Trade Desk(TTD)$ 、$星巴克(SBUX)$ 、$波音(BA)、$味好美(MKC)期权异动，后续走势如何看？查看全文
产业链观察2022-09-27 18:47
药闻▶$Ocular Therapeutix(OCUL)$ 宣布 OTX-TKI 用于治疗湿性 AMD 的美国 1 期临床试验的 7 个月中期数据:
- OTX-TKI 的耐受性良好，并显示出良好的安全性，没有发生与药物相关的眼部或全身严重不良事件（SAEs）。
- OTK-TKI治疗的受试者和Aflibercept治疗的受试者在7个月...查看全文
SeekingBiotech2022-05-10 22:30
OCUL DEXTENZA Net Product Revenue $12.5M.
Guiding DEXTENZA Annual Net Product Revenue between $55M to $60M.
Topline Data from OTX-TKI for the Treatment of Wet AMD Anticipated in Q3
Cash and cash equivalents $145M.
Affamed的合作伙伴。$Ocular Therapeutix(OCUL)$查看全文
产业链观察2021-12-06 20:51
药闻▶2021年12月6日，专注于眼部疾病和病症的创新疗法的配方、开发和商业化的生物制药公司$Ocular Therapeutix(OCUL)$ 今天宣布其用于短期治疗干眼症的OTX-DED（地塞米松眼药水）的2期临床试验取得了积极的初步结果。查看全文
产业链观察2021-10-22 21:14
药闻| 2021年10月22日，专注于眼部疾病和病症的创新疗法的配方、开发和商业化的生物制药公司$Ocular Therapeutix(OCUL)$今天宣布了其用于治疗干眼症(DED)的OTX-CSI(环孢素管内插管)2期临床试验的初步结果。
OTX-CSI的2期临床试验是在美国进行的，是一项随机、双盲、多中心、载体控制的临床试验...查看全文
Replix锐璞美股2021-05-03 22:41
$Ocular Therapeutix(OCUL)$ 我们更新了OCUL的估值模型，请查看：网页链接。
$BioNTech(BNTX)$ $Moderna(MRNA)$查看全文
$Ocular Therapeutix(OCUL)$ DEF 14A Other definitive proxy statements Accession Number: 0001558370-22-006631 Act: 34 Size: 1 MB 网页链接
$Ocular Therapeutix(OCUL)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001558370-22-006635 Act: 34 Size: 433 KB 网页链接
$Ocular Therapeutix(OCUL)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001104659-22-028186 Act: 33 Size: 477 KB 网页链接
$Ocular Therapeutix(OCUL)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001558370-22-002363 Act: 34 Size: 11 MB 网页链接
$Ocular Therapeutix(OCUL)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001104659-22-028130 Act: 33 Size: 87 KB 网页链接
$Ocular Therapeutix(OCUL)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-22-028082 Act: 34 Size: 322 KB 网页链接
$Ocular Therapeutix(OCUL)$ POSASR Post-effective Amendment to an automatic shelf registration statement Accession Number: 0001104659-22-028045 Act: 33 Size: 605 KB 网页链接
$Ocular Therapeutix(OCUL)$ 内部交易: 2022-02-23,10% Owner,SUMMER ROAD LLC ,买入,10000普通股, $4.80
$Ocular Therapeutix(OCUL)$ 内部交易: 2022-02-18,10% Owner,SUMMER ROAD LLC ,买入,40000普通股, $5.00
$Ocular Therapeutix(OCUL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001567619-22-005374 Size: 9 KB 网页链接